Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Other financing activities (2016 - 2023)

Viking Therapeutics' Other financing activities history spans 8 years, with the latest figure at $37000.0 for Q1 2023.

  • For Q1 2023, Other financing activities changed N/A year-over-year to $37000.0; the TTM value through Mar 2023 reached $56000.0, changed N/A, while the annual FY2022 figure was $22000.0, 52.17% down from the prior year.
  • Other financing activities for Q1 2023 was $37000.0 at Viking Therapeutics, up from $19000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $37000.0 in Q1 2023 and bottomed at $7000.0 in Q4 2019.
  • The 3-year median for Other financing activities is $19000.0 (2021), against an average of $21000.0.
  • The largest YoY upside for Other financing activities was 97.53% in 2019 against a maximum downside of 97.53% in 2019.
  • A 3-year view of Other financing activities shows it stood at $7000.0 in 2019, then skyrocketed by 171.43% to $19000.0 in 2021, then surged by 94.74% to $37000.0 in 2023.
  • Per Business Quant, the three most recent readings for VKTX's Other financing activities are $37000.0 (Q1 2023), $19000.0 (Q4 2021), and $7000.0 (Q4 2019).